Veradermics, Incorporated is a late clinical-stage biopharmaceutical company. The Company is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The Company is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidilâs impact on hair restoration while minimizing the risk of cardiac activity. The Company is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL.
äŒæ¥ã³ãŒãMANE
äŒç€ŸåVeradermics Inc
äžå Žæ¥Feb 04, 2026
æé«çµå¶è²¬ä»»è
ãCEOãWaldman (Reid Alexander)
åŸæ¥å¡æ°19
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Feb 04
æ¬ç€Ÿæåšå°- -
éœåž- -
蚌åžååŒæNASDAQ OMX NASDAQ Basic NYSE
åœ- -
éµäŸ¿çªå·- -
é»è©±çªå·- -
ãŠã§ããµã€ã- -
äŒæ¥ã³ãŒãMANE
äžå Žæ¥Feb 04, 2026
æé«çµå¶è²¬ä»»è
ãCEOãWaldman (Reid Alexander)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã